Teduglutide Research

Gupta R, Nainwal P, Padhi S, Srinivasan H

Posovszky C, de Laffolie J, Henning S, Ballauf A, Berrang J, Bildheim V et al.

Paediatric short bowel syndrome (SBS) with chronic intestinal failure (IF) is a rare, complex and potentially life-threatening condition. The main causes in children are necrotizing enterocolitis, volvulus, congenital malformations, and other enteropathies. The resulting reduced intestinal absorp...

Nordell P, Jansson-Löfmark R, Gennemark P

Peptide-based therapeutics represent a rapidly expanding class of drugs. Endogenous peptides typically exhibit short elimination half-lives due to proteolytic cleavage and renal filtration. However, modifications such as amino acid substitutions and fatty-acid conjugation can significantly prolon...

Scaramella L, Sorge A, Tontini GE, Fracas E, Smania V, Costantino A et al.

Safety and usefulness of double-balloon enteroscopy (DBE) in patients with short bowel syndrome (SBS) are unknown. DBE could be effective in exploring the residual small bowel (SB) entirely, in monitoring patients receiving teduglutide (TED) treatment and, if necessary, could be operative.This st...

Li H, Li Y, Liu L, Zeng B, Su S, Liu J et al.

Intestinal obstruction is a severe abdominal condition that can be triggered by various medications; however, the drugs most strongly and frequently linked to this adverse event (AE) remain insufficiently defined in the current medical literature.This study sought to systematically identify and e...

Nishina R, Hino S, Kato C, Nishimura N

Small intestinal villous atrophy, a frequent complication of cancer chemotherapy, impairs nutrient absorption and worsens participant quality of life. Although the glucagon-like peptide-2 (GLP-2) analog teduglutide can promote villus regeneration, its clinical application is limited. We hypothesi...

Josey C, Mazariegos G, King E, Holzer P, Rudolph J, Raghu VK et al.

In patients with short bowel syndrome (SBS), teduglutide reduces dependency on parenteral support (PS) by promoting intestinal growth and absorption. We aim to describe long-term outcomes using teduglutide in a large pediatric intestinal rehabilitation and transplant center.We performed a single-...

Auernhammer CJ, Wang K, Maccio U, Knösel T, Hungbauer MP, Schilbach K et al.

Precision medicine has transformed many areas in oncology. However, it remains largely unexplored in metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), where there is a need for further innovative therapies.To evaluate individual tumor responses to different agents, we have es...

Jiao P, Zhang ZJ, Jiang Y, Zhou J, Deng KH, Zhu WX et al.

Pediatric short bowel syndrome (SBS) poses management challenges, and teduglutide is a potential therapy. However, comprehensive data on its pediatric safety are lacking.To evaluate the impact of teduglutide on infection and gastrointestinal adverse events in pediatric SBS patients via systematic...

Masumoto K, Muto M, Sasaki T, Shikamura M, Tanaka T, Sakui S et al.

Patients with short bowel syndrome (SBS)-associated intestinal failure (SBS-IF) are dependent on parenteral support (PS). In Japan, teduglutide is the only GLP-2 analog medicine indicated for these patients. There are limited data for pediatric patients, especially those with a low body weight. T...

Yusta B, Wong CK, Matthews D, Koehler JA, Baggio LL, Drucker DJ et al.

Glucagon-like peptide-2 (GLP-2) reduces systemic and gut inflammation while preserving mucosal integrity. Preclinical and clinical reports implicate GLP-2 receptor (GLP-2R) agonism as a potential therapy for graft vs. host disease (GvHD).Here we assessed whether enhanced vs. loss of GLP-2R signal...

Solar Muñiz H, Fernández A, Busoni V, Martínez MI, Rumbo C, De Barrio S et al.

Approval of teduglutide is an important addition to the limited treatment options for short bowel syndrome (SBS). However, real-world evidence on teduglutide therapy for SBS in Latin America is scarce.To investigate the effectiveness and safety of teduglutide in clinical practice in Argentina wit...

Bastas A, Williams K, Wong D

Glucagon-like peptide-2 analogues are part of the treatment algorithm for chronic intestinal failure to improve enteral nutrient absorption and reduce reliance on parenteral support. The purpose of this review is to update, consolidate and comprehensively evaluate the existing body of evidence, h...

Wada M, Nakamura S, Hayashi A, Otake R, Miyamoto M, Tanaka T et al.

Patients with intestinal failure caused by short bowel syndrome (SBS) are dependent on parenteral support (PS) for nutrition. Teduglutide, an analogue of glucagon-like peptide 2, has been shown to decrease reliance on PS with an acceptable safety profile in multiregional phase 3 clinica...

Tapia-Sanchiz MS, Sampedro-Núñez MA, Jiménez-Blanco S, Molina-Baena B

Short bowel syndrome (SBS) represents one of the central conditions in clinical nutrition, with a complex and challenging management. Teduglutide, an analog of human glucagon-like peptide-2 (GLP-2), is the first approved long-term, non-symptomatic treatment for SBS. We present the case of a 62-ye...

Bordelon RC, Varalla SJ, Tammisetti VS, Shahin MM, Tchakarov A, Imseis E et al.

Teduglutide is a glucagon-like peptide 2 (GLP-2) analogue that was approved by the United States Food and Drug Administration for the treatment of pediatric (>1 year) intestinal failure due to short bowel syndrome in 2019. GLP-2 analogues promote rapid intestinal adaptation, increasing the abs...

Eldredge JA, Borg C, Couper RTL, Dehlsen K, Ee LC, Fox J et al.

Teduglutide is a glucagon-like peptide 2 analogue with demonstrated efficacy in reducing parenteral solution (PS) requirements to facilitate enteral autonomy in children with short bowel syndrome-associated intestinal failure (SBS-IF). There is currently no clear consensus on how to wean PS and m...

Liu S, Yu X, Ye F, Jiang L

Short bowel syndrome (SBS), characterized by insufficient absorptive surface after extensive intestinal resection, results in chronic intestinal failure and reliance on parenteral nutrition. This meta-analysis aimed to examine the adverse events associated with teduglutide treatment for SBS.Compr...

Du C, Liang Y, Liu W, Jiang Y, Wang Y

The purpose of this study was to explore the risks associated with drugs that lead to drug-related carcinoembryonic antigen (CEA) increased by data from the Food and Drug Administration Adverse Event Reporting System. The adverse event reports associated with drugs induced CEA increase extracted ...

Sakurai T, Kudo H, Megumi N, Ando R, Kazama T, Okubo R et al.

Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long-term parenteral nutrition (PN). Teduglutide (TED), a glucagon-like peptide-2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long-term data in ped...